Tag:

SparVax

Latest Headlines

Latest Headlines

Anthrax vax to move into new Phase II trials

June 21, 2012
PharmaThene, supported with federal funding, is developing an anti-bioterrorism anthrax vaccine, SparVax, and is planning further Phase II trials for the second half of 2012.

PharmAthene wins ruling in fight over $78M anthrax contract

FierceBiotech | June 9, 2010
PharmAthene announced that it won a brawl with rival Emergent BioSolutions, obtaining a ruling from the Government Accountability Office that allows the developer to keep a $78 million contract to
Related Tags
Press Releases
  • SHL to Invest 40 Million USD in 2013 to Significantly Expand Production Facilities
  • New Drug Combination Could Prevent Head and Neck Cancer in High-risk Patients
  • CDRD Ventures Inc. Announces New Partnership with Pfizer
  • Blaze Bioscience Announces Completion of Series A Financing - Brings Total Investment to $9.8 Million
  • FDA Approves Genentech's Kadcyla (Ado-Trastuzumab Emtansine), the First Antibody-Drug Conjugate for Treating Her2-Positive Metastatic Breast Cancer
  • More Press Releases
Featured Jobs
  • Associate Principal Informatician - Big Data Analytics
    AstraZeneca - Waltham, Massachusetts, USA
  • Scientist II Job
    Yoh - Danbury, CT, USA
  • Director of Manufacturing
    MBio Diagnostics, Inc. - Boulder, Colorado
  • Scientist Job
    Yoh - Miami, FL, USA
  • CSV Consultant - California
    ProPharma Group -
Sponsored Links